Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

"Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014" now available at Fast Market Research


Print article Print article
2014-03-30 03:59:30 - Recently published research from Global Markets Direct, "Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014", is now available at Fast Market Research

Global Markets Direct's, 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Spinal Muscular Atrophy (SMA) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Muscular Atrophy (SMA) . Spinal Muscular Atrophy (SMA) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at
- www.fastmr.com/prod/778133_spinal_muscular_atrophy_sma_pipeline_ ..

Note*: Certain sections in the report

may be removed or altered based on the availability and relevance of data for the indicated disease.

Report Scope

* A snapshot of the global therapeutic scenario for Spinal Muscular Atrophy (SMA) .
* A review of the Spinal Muscular Atrophy (SMA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Spinal Muscular Atrophy (SMA) pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Spinal Muscular Atrophy (SMA) .
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Genzyme Corporation, F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., Pfizer Inc., Paratek Pharmaceuticals, Inc., Neurotune AG, Trophos SA, Nexgenix Pharmaceuticals, LLC, Genethon, Vybion, Inc., California Stem Cell, Inc., OrphageniX, Inc., Retrophin, LLC, Neurodyn Inc., Cellular Biomedicine Group, Inc., gmp-orphan SAS

Partial Table of Contents:

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Spinal Muscular Atrophy (SMA) Overview
Therapeutics Development
Pipeline Products for Spinal Muscular Atrophy (SMA) - Overview
Pipeline Products for Spinal Muscular Atrophy (SMA) - Comparative Analysis
Spinal Muscular Atrophy (SMA) - Therapeutics under Development by Companies
Spinal Muscular Atrophy (SMA) - Therapeutics under Investigation by Universities/Institutes
Spinal Muscular Atrophy (SMA) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Spinal Muscular Atrophy (SMA) - Products under Development by Companies
Spinal Muscular Atrophy (SMA) - Products under Investigation by Universities/Institutes
Spinal Muscular Atrophy (SMA) - Companies Involved in Therapeutics Development
Genzyme Corporation
F. Hoffmann-La Roche Ltd.
Isis Pharmaceuticals, Inc.
Pfizer Inc.
Paratek Pharmaceuticals, Inc.
Neurotune AG
Trophos SA
Nexgenix Pharmaceuticals, LLC
Genethon
Vybion, Inc.
California Stem Cell, Inc.
OrphageniX, Inc.
Retrophin, LLC
Neurodyn Inc.
Cellular Biomedicine Group, Inc.
gmp-orphan SAS
Spinal Muscular Atrophy (SMA) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Assessment by Therapeutic Class
Drug Profiles
olesoxime - Drug Profile
Product Description
Mechanism of Action
R&D Progress
valproate sodium + [levocarnitine] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-SMNRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sodium phenylbutyrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-06687859 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SMN-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MotorGraft - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AAV9-SMN Gene Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=778133&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com